Categories
Change Password!
Reset Password!
Patients initiating rimegepant for acute migraine show higher treatment persistence when compared to those using oral triptans.
In a retrospective cohort analysis of US insurance claims data, migraine patients initiating treatment with rimegepant demonstrate substantially higher persistence when compared to those using traditional oral triptans. The findings suggest rimegepant could be a more effective long-term option for acute migraine care, especially for those who struggle with triptan therapies.
The study analyzed data from March 2019 through June 2023, encompassing commercially insured and US federal Medicare patients diagnosed with migraine. Researchers identified 13,599 patients who started rimegepant and 38,127 patients who began treatment with oral triptans. After matching the cohorts by propensity scores to balance baseline characteristics, 9,909 patients remained in each group for comparison. Persistence—defined as filling at least one prescription refill within 12 months of the initial treatment—was markedly higher among rimegepant users.
Nearly 75.8% of patients prescribed rimegepant remained persistent, compared to 53.5% in the oral triptan group. Statistical analysis showed that patients on rimegepant were nearly 3 times as likely to continue their medication (odds ratio [OR] 2.72). Subgroup analyses reinforced these results. When compared specifically against rizatriptan and sumatriptan, two commonly prescribed triptans, rimegepant persistence remained considerably greater (rizatriptan: OR 2.49; sumatriptan: OR 2.92). Patients with chronic migraine also exhibited increased persistence on rimegepant (OR 2.86), highlighting its potential benefit in more severe cases.
Thus, rimegepant offers a favorable alternative for migraineurs, particularly those who experience insufficient relief, adverse effects, or contraindications with oral triptans. Its higher persistence rates in real-world clinical settings suggest better tolerability and sustained effectiveness. This evidence supports rimegepant as a valuable addition to acute migraine treatment options, potentially enhancing long-term outcomes for many sufferers.
Cephalalgia
A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data
Cephalalgia
Comments (0)